Pharma BD Deal Intelligence

Halda Therapeutics, Inc. / VantAI

2025 · Co-Development · $1.0B · Pending

VantAI and Halda Therapeutics formed a strategic research collaboration worth more than $1 billion in total potential value across multiple targets. VantAI applies its Neo-1 foundation model and NeoLink structural proteomics platform to identify context-specific target-effector pairs feeding Halda's RIPTAC (Regulated Induced Proximity Targeting Chimera) "hold-and-kill" pipeline in oncology and immunology. Terms include upfront payments, research support, development and commercial milestones and tiered royalties on net sales.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals